Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04832204Phase 2Unknown

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

Role: collaborator

NCT02902432Phase 2Unknown

A Trial of Endostar in Patients With Carcinoma of the Head and Neck

Role: collaborator

NCT03654612Phase 1Unknown

Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies

Role: collaborator

All 3 trials loaded